Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin

Kidney International, Supplement

Volumn 64, Issue 87, 2003, Pages

  Avram, Morrell Michael ^a   Blaustein, Daniel ^a   Fein, Paul A ^a   Goel, Naveen ^a   Chattopadhyay, Jyotiprakas ^a   Mittman, Neal ^a  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

Author keywords

Anemia; Dialysis; Nutrition; Prealbumin; Survival

Indexed keywords

HEMOGLOBIN; PREALBUMIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GENDER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; KAPLAN MEIER METHOD; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTIVARIATE ANALYSIS; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; RACE; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; FOLLOW UP; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ADULT; AGED; ANEMIA; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREALBUMIN; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0142200422     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.64.s87.3.x     Document Type: Article

References (33)

1. ESCHBACH JW, ADAMSON JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28:1-5, 1985
2. FOLEY RN, PARFREY PS, HARNETT JD, et al: The impact of anemia on cardiomyopathy, morbidity, and mortality in endstage renal disease. Am J Kidney Dis 28:53-61, 1996
3. SILVERBERG DS, WEXLER D, BLUM M: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744, 2000
4. ACCHIARDO SR, MOORE LW, LATOUR PA: Malnutrition as the main factor in morbidity and mortality of dialysis patients. Kidney Int 24:S199-S203, 1983
5. AVRAM MM, MITTMAN N, BONOMINI L, et al: Markers for survival in dialysis: A seven year prospective study. Am J Kidney Dis 26:209-219, 1995
6. AVRAM MM, BONOMINI LV, SREEDHARA R, et al: Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis 28:910-917, 1996
7. AVRAM MM, SREEDHARA R, FEIN PA, et al: Survival of hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters. Am J Kidney Dis 37:S77-S80, 2001
8. LOWRIE EG, LEW NL: Death risk in hemodialysis: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-463, 1990
9. AVRAM MM: Prealbumin - A nutritional marker-predicts survival in dialysis patients. Dial Times 8:1-6, 2001
10. MITTMAN N, AVRAM MM, Oo KK, et al: Serum prealbumin predicts survival in hemodialysis and peritoneal dialysis: 10 years of prospective observation. Am J Kidney Dis 38:1358-1364, 2001
11. GOLDWASSER P, MICHEL M-A, COLLIER J, et al: Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival. Am J Kidney Dis 22:215-225, 1993
12. CHERTOW GM, ACKERT K, LEW NL, et al: Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 58:2512-2517, 2000
13. KAPLAN EL, MEIER P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. ANAND IS, CHANDRASHEKHAR Y, FERRARI R, et al: Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, hemodynamic variables, and plasma hormones. Br Heart J 70:357-362, 1993
15. DUKE M, ABELMANN WH: The hemodynamic response to chronic anemia. Circulation 39:503-515, 1969
16. METIVIER F, MARCHAIS SJ, GUERIN AP, et al: Pathophysiology of anaemia: Focus on the heart and blood vessels. Nephrol Dial Transplant 15:S14-S18, 2000
17. AVRAM MM, FEINFELD DA, HUATUCO AH: Search for the uremic toxin: Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. N Engl J Med 298:1000-1003, 1978
18. AVRAM MM, ALEXIS H, RAHMAN M, et al: Decreased transfusional requirement following parathyroidectomy in long term hemodialysis. Proc Am Soc Nephrol 5:5, 1971
19. AVRAM MM, IANCU M, MORROW P, et al: Uremic syndrome in man: New evidence for parathormone as a multisystem neurotoxin. Clin Nephrol 11:59-62, 1979
20. COLLINS A: Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int 61:S44-S48, 2002
21. OFSTHUN N, LABRECQUE J, LACSON E, et al: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:1908-1914, 2003
22. KEANE WF, BRENNER BM, DE ZEEUW D, et al: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63:1499-1507, 2003
23. ROBERT J, MCCLELLAN WM, ROGER SD, et al: Epoetin treatment: What are the arguments to expect a beneficial effect on renal disease progression? Nephrol Dial Transplant 17:359-362, 2002
24. JUNGERS P, CHOUKROUN G, OUALIM Z, et al: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312, 2001
25. KURIYAMA S, TOMONARI H, YOSHIDA H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
26. HAYASHI T, SUZUKI A, SHOJI T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
27. TARNG DC, HUANG TP, DOONG TI: Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron 78:253-259, 1998
28. AVRAM MM, FEIN PA, ANTIGNANI A, et al: Cholesterol and lipid disturbances in renal disease: The natural history of the uremic dyslipidemia and the impact of hemodialysis and peritoneal dialysis. Am J Med 87:55N-60N, 1989
29. NISSENSON A, GOODNOUGH LT: Anemia. Not just an innocent bystander. Arch Intern Med 163:1400-1403, 2003
30. MITTMAN N: Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond. Am J Kidney Dis 34:173-176, 1999
31. BLAUSTEIN D, SCHWENK M, CHATTOPADHYAY J, et al: The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int, 2003
32. BLOCK GA, MARTIN KJ, TURNER SA, et al: Cinacalcet HCl for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med 2003. In press
33. MACDOUGALL I: CREATE: New strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 18:13-16, 2003